Jump to content

Talk:Deferiprone

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

cormedix

[edit]

just a note - today I removed the following: "Deferiprone is in clinical trials in the United States to treat Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; the trials are being conducted by the biotech company, Cormedix.(ref)http://www.cormedix.com/pipeline_CRMD001.php(/ref)." This is no longer true - see here http://www.dailyfinance.com/2013/03/27/cormedix-reports-year-end-2012-financial-results/ and here http://philadelphia.citybizlist.com/article/sec-filing-cormedix-terminates-agreement-shiva-biomedical. We should have had some MEDRS compliant source on this and we never did... Jytdog (talk) 10:42, 1 October 2013 (UTC)[reply]

Inhibition of HIV-1 gene expression

[edit]

Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A

Mainul Hoque, Hartmut M Hanauske-Abel, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi Gandolfi, Myung Hee Park, Tsafi Pe'eryEmail author and Michael B Mathews author

Retrovirology 20096:90

DOI: 10.1186/1742-4690-6-90

https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-6-90

Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infect ... http://dx.doi.org/10.1371/journal.pone.0154842
The finding that the medicinal chelator deferiprone removes, without eliciting viral resistance noticeable in our system, the HIV-1 genome by apoptotic fragmentation preferentially of the infected cells’ DNA, defines a unique antiretroviral profile. However, HIV-1 infection usually is not associated with iron overload, and therefore any as-is repurposing of orally administered deferiprone for its antiretroviral side-activity must not be expected to be benign: We have not shown oral deferiprone to be safe or effective for anti(retro)viral indications.
It remains to be established whether any of the currently available oral preparations of deferiprone, or the anticipated chemical optimization of this pioneer drug into non-chelating inhibitors of DOHH, will translate into real benefits for persons living with HIV-AIDS. Based on the preclinical and clinical results presented here and earlier [28,43,45,46], a follow-up clinical trial evaluating the safety, efficacy, and pharmacokinetics of deferiprone in HIV-positive subjects has been conducted and is registered at ClinicalTrial.gov (NCT02456558).
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154842 — Preceding unsigned comment added by 95.33.229.87 (talk) 19:31, 24 August 2016 (UTC)[reply]
That is really exciting but it is a primary source and per WP:MEDRS we use literature reviews to source content in WP. Are you aware of any that discuss the work published in PLoS? Jytdog (talk) 05:00, 25 August 2016 (UTC)[reply]